Tasly, ProteoTech sign Alzheimer drug Exebryl-1 development agreement
The collaboration will focus on moving the clinical development of Exebryl-1 though the regulatory process in China and the US. Exebryl-1 has been shown to inhibit beta-amyloid protein
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.